Ignite Creation Date:
2025-12-24 @ 3:00 PM
Ignite Modification Date:
2026-03-01 @ 8:42 AM
Study NCT ID:
NCT04720859
Status:
UNKNOWN
Last Update Posted:
2021-01-29
First Post:
2021-01-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007003', 'term': 'Hypoglycemia'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068896', 'term': 'Canagliflozin'}, {'id': 'D013607', 'term': 'Tablets'}], 'ancestors': [{'id': 'D013876', 'term': 'Thiophenes'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D005960', 'term': 'Glucosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D004304', 'term': 'Dosage Forms'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Intervention arm in patients that present postprandial hypoglycemia following gastric by-pass and a control group of healthy subjects without intervention.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 40}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2018-01-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-01', 'completionDateStruct': {'date': '2022-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-01-26', 'studyFirstSubmitDate': '2021-01-19', 'studyFirstSubmitQcDate': '2021-01-19', 'lastUpdatePostDateStruct': {'date': '2021-01-29', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-01-22', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-12-20', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'response to OGTT in basal conditions and after treatment with canagliflozin 300 mg in patients with PHH after RYGB', 'timeFrame': 'Baseline to 180 minutes', 'description': 'The OGTTis performed as follows: a solution of 100g glucose is administered at 8am after 10 hours of fasting. Plasma glucose and serum insulin were measured at minute -5, +30, +60, +120, +180 after the ingestion of the glucose solution. A first OGTT was performed in basal conditions. The control group only performed the basal OGTT. A value of plasma glucose below 50mg/dl at 60-180 minutes after the administration of the glucose solution is considered positive for PHH. The patients that additionally presented a value of plasma glucose\\>200mg/dl during the OGTT were selected for continuing in the study and were prescribed canagliflozin 300mg orally daily, during two weeks, and 100g glucose OGTT was repeated.'}], 'secondaryOutcomes': [{'measure': 'Presence of nesidioblastosis', 'timeFrame': '30 minutes', 'description': 'By evaluating pancreatic response to intra-arterial calcium stimulation. The right femoral artery is catheterized with another 4.1 Fr, followed by standard pancreatic arteriography, with selective injections of nonionic contrast agent into the superior mesenteric artery, gastroduodenal artery, splenic artery and common hepatic artery. Following each selective arteriogram, 10% calcium gluconate solution is diluted with normal saline into a 5 mL bolus and injected into the selective artery at a dose of 0.010-0.025 mEq Ca2+/kg. A \\>2-fold gradient in insulin concentration at 30, 60, 90 or 120 seconds after the arterial calcium injection and baseline in any of the superior mesenteric artery, gastroduodenal artery, splenic artery and common hepatic artery was defined as a positive response for endogenous hyperinsulinism.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Postprandial Hypoglycemia']}, 'descriptionModule': {'briefSummary': 'Roux-en-Y gastric bypass (RYGB) is the most common surgical procedure for morbid obesity. However, it can present serious late complications, like postprandial hyperinsulinemic hypoglycemia (PHH). Recent data suggested an increase in intestinal SGLT1 after RYGB. However, there are no data on the inhibition of SLGT1 to prevent PHH in patients with prior RYBG.\n\nObjectives: To evaluate in patients that present PHH after RYGB: a) the effect of canagliflozin 300mg on the response to 100g glucose overload (OGTT); b) the pancreatic response after intra-arterial calcium stimulation.\n\nMaterial and methods: Prospective pilot study, including patients with PHH after RYGB, matched by age and gender with healthy controls. Basal OGTT and after 2-weeks of daily 300mg of canagliflozin will be performed. In addition, venous sampling after intra-arterial calcium stimulation of the pancreas will be performed.', 'detailedDescription': 'A prospective opened, placebo uncontrolled, pilot interventional study is performed at the Morbid Obesity Unit of the Vall Hebron University Hospital, including patients that have previously undergone RYGB at our site and were diagnosed with PHH. The control group comprises of healthy normoweight persons matched by age, most of them family members of patients included in the study. The OGTT is performed as follows: a solution of 100g glucose was administered at 8am after 10 hours of fasting. Plasma glucose and serum insulin are measured at minute -5, +30, +60, +120, +180 after the ingestion of the glucose solution. A first OGTT is performed in basal conditions. The control group only will perform the basal OGTT. A value of plasma glucose below 50mg/dl at 60-180 minutes after the administration of the glucose solution is considered positive for PHH. The patients that additionally present a value of plasma glucose\\>200mg/dl during the OGTT will be selected for continuing in the study and will be prescribed canagliflozin 300mg orally daily, during 2 weeks. After 2 weeks of canagliflozin treatment, a new OGTT will be performed and, in the patients that sign the additional inform consent, the pancreatic catheterism will be realized.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients diagnosed with PHH following Roux-en-Y-gastric by-pass, by means of 100g Glucose OGTT. Plasma glucose \\<50mg/dl.\n* Patients that during any time of the OGTT present at least one value of plasma glucose \\>200mg/dl, besides hypoglycemia\n\nExclusion Criteria:\n\n* Patients unwilling to take canagliflozin 300mg\n* Patients that present with PHH following other bariatric surgery techniques'}, 'identificationModule': {'nctId': 'NCT04720859', 'acronym': 'CANA-PHH-RYGB', 'briefTitle': 'Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)', 'organization': {'class': 'OTHER', 'fullName': "Hospital Universitari Vall d'Hebron Research Institute"}, 'officialTitle': 'Canagliflozin: a New Therapeutic Option in Patients That Present Postprandial Hyperinsulinemic Hypoglycemia After Roux-en-Y-gastric By-pass', 'orgStudyIdInfo': {'id': 'PR(AG)84/2018'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Patients with PHH following Roux-en-Y-gastric bypass (cases)', 'description': 'Patients diagnosed with PHH following Roux-en-Y-gastric bypass.', 'interventionNames': ['Drug: Canagliflozin 300 MG Oral Tablet']}, {'type': 'NO_INTERVENTION', 'label': 'Healthy individuals (controls)', 'description': 'Healthy normoweight individuals, matched by age and gender with the cases.'}], 'interventions': [{'name': 'Canagliflozin 300 MG Oral Tablet', 'type': 'DRUG', 'description': 'Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.', 'armGroupLabels': ['Patients with PHH following Roux-en-Y-gastric bypass (cases)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '08035', 'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Andreea Ciudin, Prof', 'role': 'CONTACT', 'email': 'aciudin@vhebron.net', 'phone': '697817352', 'phoneExt': '6591'}, {'name': 'Enzamaria Fidilio, MD', 'role': 'CONTACT', 'email': 'enzamaria.fidilio@vhir.org', 'phoneExt': '6591'}, {'name': 'Marta Sanchez, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Irene Hernandez, BS', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Efrain Cordero, BS', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Enzamaria Fidilio, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Marta Comas, Nutritionist', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Carla Gonzalez, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Natividad Lopez, Nurse', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Ramon Vilallonga, Prof', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Cristina Hernandez, Prof', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Rafael Simo, Prof', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Andreea Ciudin', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}], 'centralContacts': [{'name': 'Andreea Ciudin, Prof.', 'role': 'CONTACT', 'email': 'aciudin@vhebron.net', 'phone': '697817352', 'phoneExt': '6591'}, {'name': 'Enzamaria Fidilio, MD', 'role': 'CONTACT', 'email': 'enzamaria.fidilio@vhir.org', 'phoneExt': '6591'}], 'overallOfficials': [{'name': 'Andreea Ciudin, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Vall Hebron University Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Hospital Universitari Vall d'Hebron Research Institute", 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Associated Professor, PhD, MD, Head of the Morbid Obesity Unit', 'investigatorFullName': 'Andreea Ciudin', 'investigatorAffiliation': "Hospital Universitari Vall d'Hebron Research Institute"}}}}